

Cassava Sciences, Inc. (NASDAQ: SAVA) is a clinical-stage biotechnology company developing a novel drug treatment for Alzheimer's disease, and an investigational diagnostic to detect Alzheimer's with a simple blood test.

INVESTMENT HIGHLIGHTS

Cassava Sciences has reported positive Phase 2a results of lead product candidate, PTI-125, in patients with Alzheimer's disease.

- PTI-125 is a small molecule drug with a novel mechanism of action: it restores the normal shape/function of Filamin A (FLNA), a protein that misfolds in the Alzheimer's brain.
- In a Phase 2a study funded by the National Institutes of Health (NIH), treatment with PTI-125 for 28 days significantly reduced key biomarkers of neuroinflammation and neurodegeneration in patients ($p < 0.001$).
- Clinical results support PTI-125 as a new, highly differentiated and, potentially, disease-modifying treatment for Alzheimer's patients.
- An NIH-funded Phase 2b study in Alzheimer's patients (N=60) with PTI-125 was initiated September 2019.


The underlying science for PTI-125 is published in peer-reviewed journals and benefits from long-term scientific & financial support from NIH.

KEY FINANCIALS

(as of 9/30/19)

- ▶ \$17.8 MM cash & cash equivalents
- ▶ <\$5.0 MM net cash use in 2019
- ▶ 17.2 MM shares outstanding, plus 9.1 MM warrants outstanding
- ▶ \$78.7 MM pre-tax NOLs
- ▶ No debt


Cassava Sciences is also developing PTI-125Dx, an investigational diagnostic to detect Alzheimer's with a simple blood test.



UNIQUE SCIENTIFIC APPROACH

The biology of the brain is heavily regulated by Filamin A, a scaffolding protein. FLNA interacts with at least 90 different proteins, which makes it critical to proper cell structure, cell function and signaling pathways.

However, in Alzheimer's FLNA takes on an altered conformation. Altered FLNA enables the massive neuroinflammation and neuropathology observed in Alzheimer's disease.




PTI-125 binds to altered FLNA and restores its normal shape and function.

Healthy Filamin A (FLNA):

- Proper cell structure
- Proper cell signaling
- Proper cell function



Healthy, Elderly Brain




Altered FLNA:

- Dysfunctional cell signaling
- Impaired cell function
- Unstable cell structure



Patient with Alzheimer's




PTI-125 STABILIZES ALTERED FLNA

Significantly improved brain health in animal testing


Reduced amyloid and tau deposits



Reduced neuroinflammation



Improved insulin receptor signaling



Improved learning and memory

